US FDA lifts hold on BioSante's GVAX prostate cancer vaccine programme
This article was originally published in Scrip
Executive Summary
The US FDA has lifted a clinical hold on BioSante Pharmaceuticals’ GVAX prostate cancer vaccine programme, with investors giving the firm a 4.3% bounce, or a gain of 13 cents, before the stock closed at $3 on 6 June, down 1 cent.